Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02965976 · ClinicalTrials.gov registry record · Phase 2
Botulinum Toxin Type A in Preventing Complications After Surgery in Patients With Esophageal Cancer
A Phase 2 study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT02965976 is a Phase 2 study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 33 participants.
The verdict
NCT02965976, a Phase 2 study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
This randomized phase II trial studies how well botulinum toxin type A works in preventing complication after surgery in patients with esophageal cancer. Botulinum toxin type A may cause less complications of nausea and vomiting after surgery.
Interventions
- OTHER Quality-of-Life Assessment
- PROCEDURE Esophagectomy
- BIOLOGICAL Botulinum Toxin Type A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2016-12-30 |
| Est. Completion | 2022-04-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02965976
The ClinicalTrials.gov registry entry for NCT02965976 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Quality-of-Life Assessment is the first listed.
NCT02965976 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02965976 about?
NCT02965976 is a clinical study titled "Botulinum Toxin Type A in Preventing Complications After Surgery in Patients With Esophageal Cancer". This randomized phase II trial studies how well botulinum toxin type A works in preventing complication after surgery in patients with esophageal cancer. Botulinum toxin type A may cause less complications of nausea and vomiting after surgery.
What is the current status of trial NCT02965976?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2016-12-30. Estimated completion is 2022-04-28.
What interventions are being tested in trial NCT02965976?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Esophagectomy (PROCEDURE), Botulinum Toxin Type A (BIOLOGICAL).
Who is sponsoring clinical trial NCT02965976?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.